Altus Formulation Inc.

The value-added medicines industry has welcomed a new addition to its ranks. Canadian firm Altus Formulation and UAE-based Spektar Therapeutics have joined forces and launched a new specialty compan

Teva Pharmaceutical Industries Ltd. 's in vitro and human abuse potential study data comparing its Vantrela ER to the original formulation of Pernix Therapeutics Holdings Inc. 's Zohydro ER le

Financings Representing a 72% increase over Q4 2014, first-quarter 2015 financing totaled $15.1 billion and featured 187 transactions (52 more than Q4). ( See Exhibit 1. ) Exhibit 1 Q1 2015 Biopharma

FDA is considering when it should deny approval or withdraw approval of opioids that lack abuse-deterrent features and sought input on the issue during a two-day public meeting. The Oct. 30-31 meeting